DISCO Pharmaceuticals GmbH
Roman Thomas is an accomplished entrepreneur and academic with significant experience in the fields of genomics and biotechnology. As the Founder and CEO of DISCO Pharmaceuticals GmbH since May 2022, Roman also holds the position of Professor and Chair in the Department of Translational Genomics at the University of Cologne, where Roman has been active since December 2011. Roman's entrepreneurial ventures include founding Epiphanes Inc., Pear River Bio, and Blackfield/NEO New Oncology AG, with the latter two companies being acquired by Centessa Pharmaceuticals and Siemens Healthcare, respectively. Prior experience includes serving as a Principal Investigator at the Max Planck Society from 2007 to 2011. Roman's educational background includes a Doctor of Medicine degree from the University of Cologne and postdoctoral fellowships at the Broad Institute of M.I.T. and Harvard and Dana-Farber Cancer Institute.
This person is not in any teams
DISCO Pharmaceuticals GmbH
DISCO’s pioneering surfaceome mapping platform transforms the current approach of target discovery for large molecule R&D. The technology identifies proteins and protein communities across the entire cancer cell surface in a scalable manner, thus addressing the need for target candidates for both mono- and bi-specific antibodies. These insights enable the development of a multitude of cancer-selective therapies, with the potential to boost efficacy and reducing side effects for patients.